^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Basal Cell Carcinoma

    Related cancers:
    1d
    Electrochemotherapy for Effective Keratinocyte Cancer Cure (ELE-Cure) (ACTRN12626000249358)
    P4, N=40, Not yet recruiting, The University of Sydney
    New P4 trial
    7d
    ARTACUS: Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies (clinicaltrials.gov)
    P1/2, N=90, Recruiting, Replimune Inc. | N=65 --> 90 | Trial completion date: Jan 2028 --> Nov 2029 | Trial primary completion date: Sep 2027 --> Jul 2029
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Tudriqev (vusolimogene oderparepvec-wtpg)
    8d
    A Treatment Decision Model for Cutaneous Squamous Cell Carcinoma Based on Bayesian Networks. (PubMed, Cancers (Basel))
    Our results suggest that BNs are a valuable tool for representing complex clinical decision-making processes.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Libtayo (cemiplimab-rwlc)
    10d
    LegitHealth PH: Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions. (clinicaltrials.gov)
    P=N/A, N=9, Completed, AI Labs Group S.L
    New trial
    15d
    Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery (clinicaltrials.gov)
    P2, N=70, Recruiting, Thomas Jefferson University | N=35 --> 70
    Enrollment change
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    18d
    L19IL2/TNF in patients with basal cell carcinoma (2025-523230-77-00)
    P1/2, N=53, Not yet recruiting, Philogen S.p.A.
    New P1/2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    18d
    PHL19IL2TNFCOMB04/24: L19IL2 or L19TNF or L19IL2/TNF in patients with basal cell carcinoma (BCC) (2025-523229-16-00)
    P1/2, N=85, Not yet recruiting, Philogen S.p.A.
    New P1/2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    19d
    Basal Cell Carcinoma in Perianal Region: A Rare Case Presentation and Review of Literatures. (PubMed, Cureus)
    History and physical examinations were performed on every follow-up. Patient is recurrence-free till the last follow-up.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    22d
    Histological and Genetic Markers of Cellular Senescence in Keratinocyte Cancers and Actinic Keratosis: A Systematic Review. (PubMed, Int J Mol Sci)
    Study heterogeneity, variable antibody scoring, and limited assessment of senescence-associated beta-galactosidase and secretory mediators restricted cross-study comparability. Standardized, spatially resolved profiling may refine risk stratification and support senescence-targeted prevention and therapy in keratinocyte cancers.
    Review • Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • PVT1 (Pvt1 Oncogene) • MAPK8 (Mitogen-activated protein kinase 8) • MAPK9 (Mitogen-Activated Protein Kinase 9)
    24d
    Basal Cell Carcinoma With Matrical Differentiation Case Report and Review of Management. (PubMed, Cureus)
    Rare reports of metastasis suggest a potentially more aggressive clinical course than typical BCC. Comprehensive excision and long-term surveillance are recommended to optimize outcomes and further characterize this rare variant.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • TCHH (Trichohyalin)
    26d
    SJFAMILY: Familial Investigations of Childhood Cancer Predisposition (clinicaltrials.gov)
    P=N/A, N=1500, Recruiting, St. Jude Children's Research Hospital | N=3000 --> 1500
    Enrollment change
    29d
    LEAH: Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals (clinicaltrials.gov)
    P=N/A, N=5909, Not yet recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Initiation date: Jun 2025 --> Feb 2026
    Trial initiation date
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • POLE (DNA Polymerase Epsilon) • RUNX1 (RUNX Family Transcription Factor 1) • BAP1 (BRCA1 Associated Protein 1) • ETV6 (ETS Variant Transcription Factor 6) • MLH1 (MutL homolog 1) • CDK4 (Cyclin-dependent kinase 4) • MSH2 (MutS Homolog 2) • SMAD4 (SMAD family member 4) • CDH1 (Cadherin 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • POLD1 (DNA Polymerase Delta 1) • RAD51C (RAD51 paralog C) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • RAD51D (RAD51 paralog D) • DDX41 (DEAD-Box Helicase 41) • GATA2 (GATA Binding Protein 2) • DICER1 (Dicer 1 Ribonuclease III) • FLCN (Folliculin) • PRSS1 (Serine Protease 1) • SDHD (Succinate Dehydrogenase Complex Subunit D) • TXNIP (Thioredoxin Interacting Protein) • ANKRD26 (Ankyrin Repeat Domain Containing 26) • BMPR1A (Bone Morphogenetic Protein Receptor Type 1A) • HOXB13 (Homeobox B13)
    |
    TP53 mutation • PTEN deletion